Search

Vetoquinol SA

Fermé

SecteurSoins de santé

86.8 1.17

Résumé

Variation du prix de l'action

24h

Actuel

Min

86.8

Max

86.9

Chiffres clés

By Trading Economics

Revenu

25M

Ventes

258M

P/E

Moyenne du Secteur

16.824

87.826

Rendement du dividende

1.05

Marge bénéficiaire

9.734

Employés

2,497

EBITDA

48M

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.05%

2.26%

Prochains Résultats

19 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1B

Ouverture précédente

85.63

Clôture précédente

86.8

Sentiment de l'Actualité

By Acuity

50%

50%

187 / 370 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Vetoquinol SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 janv. 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 janv. 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

9 janv. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 janv. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 janv. 2026, 21:43 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 janv. 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 janv. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 janv. 2026, 20:36 UTC

Acquisitions, Fusions, Rachats

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 janv. 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 janv. 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 janv. 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9 janv. 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 janv. 2026, 19:58 UTC

Acquisitions, Fusions, Rachats

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 janv. 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 janv. 2026, 19:38 UTC

Acquisitions, Fusions, Rachats

Wolters Kluwer Acquires StandardFusion >WTKWY

9 janv. 2026, 19:31 UTC

Résultats

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 janv. 2026, 19:28 UTC

Résultats

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 janv. 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 janv. 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 janv. 2026, 17:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

9 janv. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 janv. 2026, 17:19 UTC

Market Talk

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 janv. 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 janv. 2026, 17:07 UTC

Market Talk

McDonald's Promotions Appear Successful -- Market Talk

9 janv. 2026, 17:06 UTC

Market Talk

Oil Futures on Track for Weekly Gains -- Market Talk

9 janv. 2026, 17:05 UTC

Résultats

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9 janv. 2026, 16:57 UTC

Market Talk

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9 janv. 2026, 16:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 janv. 2026, 16:46 UTC

Market Talk

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Vetoquinol SA prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

72.6 / 75.1Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

187 / 370Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat